PCRX

SEC source: 0001209191-19-035086 · doc4.xml · nonDerivative · entry 1

HASTINGS PAUL J · CIK 0001309702 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,747

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

SEC source: 0001209191-19-035123 · doc4.xml · nonDerivative · entry 1

Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,268

F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

F2 · balance_after: Includes 761 shares of common stock acquired under the issuer's employee stock purchase plan in December 2018.

SEC source: 0001209191-19-035098 · doc4.xml · nonDerivative · entry 1

LARANJEIRA CHARLES ANTHONY · CIK 0001524338 · SVP, Technical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,367

F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

F2 · balance_after: Includes 559 shares of common stock acquired under the issuer's employee stock purchase plan in December 2018.

SEC source: 0001209191-19-035115 · doc4.xml · nonDerivative · entry 1

McLoughlin Dennis · CIK 0001752004 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,822

F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

F2 · balance_after: Includes 88 shares of common stock acquired under the issuer's employee stock purchase plan in December 2018.

SEC source: 0001209191-19-035141 · doc4.xml · nonDerivative · entry 1

WINSTON ROY · CIK 0001751757 · Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,539

F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

F2 · balance_after: Includes 761 shares of common stock acquired under the issuer's employee stock purchase plan in December 2018.

SEC source: 0001209191-19-034738 · doc4.xml · derivative · entry 5

Scranton Richard · CIK 0001709330 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires 2022-06-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock options are fully vested.

SEC source: 0001209191-19-034738 · doc4.xml · derivative · entry 4

Scranton Richard · CIK 0001709330 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,010 shares

Expires 2022-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock options are fully vested.

SEC source: 0001209191-19-034738 · doc4.xml · nonDerivative · entry 3

Scranton Richard · CIK 0001709330 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,101

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.14 to $43.49, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-19-034738 · doc4.xml · nonDerivative · entry 2

Scranton Richard · CIK 0001709330 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,611

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001209191-19-034738 · doc4.xml · nonDerivative · entry 1

Scranton Richard · CIK 0001709330 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,111

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001209191-19-018092 · doc4.xml · nonDerivative · entry 2

Kronenfeld Mark A. · CIK 0001578074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,277

SEC source: 0001209191-19-018092 · doc4.xml · nonDerivative · entry 1

Kronenfeld Mark A. · CIK 0001578074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,277

SEC source: 0001209191-18-063670 · doc4.xml · derivative · entry 6

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,856

Underlying: Common Stock · 6,000 shares

Expires 2020-12-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested as to 25% of the option shares on December 29, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.

SEC source: 0001209191-18-063670 · doc4.xml · derivative · entry 5

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,000

Underlying: Common Stock · 6,000 shares

Expires 2020-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vested as to 50% of the option shares on February 2, 2011, 19,377 option shares vested on February 3, 2011, and the remaining option shares vested in successive equal monthly installments for the subsequent 19 months.

SEC source: 0001209191-18-063670 · doc4.xml · nonDerivative · entry 2

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-063670 · doc4.xml · nonDerivative · entry 1

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-18-013904 · edgar.xml · nonDerivative · entry 2

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 950,362

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.45 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.

F2 · ownership.nature: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) ("HBM")is exercised by the board of directors of HBM. The board of directors of HBM consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001179110-18-013904 · edgar.xml · nonDerivative · entry 1

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 959,082

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.50 to $48.36 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.

F2 · ownership.nature: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) ("HBM")is exercised by the board of directors of HBM. The board of directors of HBM consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-18-059710 · doc4.xml · nonDerivative · entry 1

PACE GARY W · CIK 0001184778 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,819

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $45.92 to $46.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001179110-18-013103 · edgar.xml · nonDerivative · entry 1

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 964,889

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.03 to $47.25 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.

F2 · ownership.nature: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) ("HBM")is exercised by the board of directors of HBM. The board of directors of HBM consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001179110-18-013021 · edgar.xml · nonDerivative · entry 4

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 965,879

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.11 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote five (5) of this Form 4.

F2 · ownership.nature: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) ("HBM")is exercised by the board of directors of HBM. The board of directors of HBM consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001179110-18-013021 · edgar.xml · nonDerivative · entry 3

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 969,379

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.7132 to $46.97 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote four (4) of this Form 4.

F2 · ownership.nature: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) ("HBM")is exercised by the board of directors of HBM. The board of directors of HBM consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-18-059156 · doc4.xml · nonDerivative · entry 2

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,683

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.57 to $47.975, inclusive.

SEC source: 0001209191-18-059156 · doc4.xml · nonDerivative · entry 1

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,241

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.57 to $47.56, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.

SEC source: 0001179110-18-013021 · edgar.xml · nonDerivative · entry 2

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See fotnote.

Disclosed balance after: 991,479

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.50 to $48.21 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.

F2 · ownership.nature: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) ("HBM")is exercised by the board of directors of HBM. The board of directors of HBM consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001179110-18-013021 · edgar.xml · nonDerivative · entry 1

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 1,010,288

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.22 to $47.84 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.

F2 · ownership.nature: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) ("HBM")is exercised by the board of directors of HBM. The board of directors of HBM consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001179110-18-012862 · edgar.xml · nonDerivative · entry 1

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 1,036,377

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $$49.83 to $49.8328 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.

F2 · ownership.nature: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) ("HBM")is exercised by the board of directors of HBM. The board of directors of HBM consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001179110-18-012808 · edgar.xml · nonDerivative · entry 2

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 1,041,855

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.21 to $50.25 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.

F2 · ownership.nature: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) ("HBM")is exercised by the board of directors of HBM. The board of directors of HBM consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001179110-18-012808 · edgar.xml · nonDerivative · entry 1

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 1,042,761

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.96 to $51.22 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.

F2 · ownership.nature: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) ("HBM")is exercised by the board of directors of HBM. The board of directors of HBM consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-18-057963 · doc4.xml · nonDerivative · entry 1

PACE GARY W · CIK 0001184778 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,319

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $50.98 to $51.69, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-18-057394 · doc4.xml · derivative · entry 3

Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 1,000 shares

Expires 2021-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on May 2, 2012 and vested as to the remaining shares in successive equal monthly installments over the subsequent 36 months.

SEC source: 0001209191-18-057394 · doc4.xml · nonDerivative · entry 2

Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,474

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001209191-18-057394 · doc4.xml · nonDerivative · entry 1

Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,474

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001209191-18-054974 · doc4.xml · derivative · entry 8

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,856

Underlying: Common Stock · 15,000 shares

Expires 2020-12-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested as to 25% of the option shares on December 29, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.

SEC source: 0001209191-18-054974 · doc4.xml · derivative · entry 7

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 18,190 shares

Expires 2020-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vested as to 50% of the option shares on February 2, 2011, 19,377 option shares vested on February 3, 2011, and the remaining option shares vested in successive equal monthly installments for the subsequent 19 months.

SEC source: 0001209191-18-054974 · doc4.xml · derivative · entry 6

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,810 shares

Expires 2020-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vested as to 50% of the option shares on February 2, 2011, 19,377 option shares vested on February 3, 2011, and the remaining option shares vested in successive equal monthly installments for the subsequent 19 months.

SEC source: 0001209191-18-054974 · doc4.xml · nonDerivative · entry 3

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-054974 · doc4.xml · nonDerivative · entry 2

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-054974 · doc4.xml · nonDerivative · entry 1

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,493

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-052315 · doc4.xml · derivative · entry 3

Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 1,000 shares

Expires 2021-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on May 2, 2012 and vested as to the remaining shares in successive equal monthly installments over the subsequent 36 months.

SEC source: 0001209191-18-052315 · doc4.xml · nonDerivative · entry 2

Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,474

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001209191-18-052315 · doc4.xml · nonDerivative · entry 1

Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,474

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001209191-18-050102 · doc4.xml · derivative · entry 1

McLoughlin Dennis · CIK 0001752004 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2028-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on August 29, 2019, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

SEC source: 0001209191-18-048951 · doc4.xml · nonDerivative · entry 1

Kronenfeld Mark A. · CIK 0001578074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,577

SEC source: 0001209191-18-048389 · doc4.xml · nonDerivative · entry 1

Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,474

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.35 to $44.60, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-18-047110 · doc4.xml · derivative · entry 8

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,481 shares

Expires 2022-06-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The stock option vested as to 25% of the option shares on June 5, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.

SEC source: 0001209191-18-047110 · doc4.xml · derivative · entry 7

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 610 shares

Expires 2020-12-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The stock option vested as to 25% of the option shares on December 29, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.

SEC source: 0001209191-18-047110 · doc4.xml · nonDerivative · entry 4

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,683

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.40 to $48.00, inclusive.

SEC source: 0001209191-18-047110 · doc4.xml · nonDerivative · entry 3

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,547

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $47.375, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4.

SEC source: 0001209191-18-047110 · doc4.xml · nonDerivative · entry 2

STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,745

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.